(NYSE: HAE) Haemonetics's forecast annual revenue growth rate of 2.74% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Haemonetics's revenue in 2025 is $1,360,824,000.On average, 4 Wall Street analysts forecast HAE's revenue for 2026 to be $62,330,500,234, with the lowest HAE revenue forecast at $61,577,664,432, and the highest HAE revenue forecast at $62,695,485,329. On average, 4 Wall Street analysts forecast HAE's revenue for 2027 to be $66,476,957,655, with the lowest HAE revenue forecast at $64,741,380,989, and the highest HAE revenue forecast at $67,603,425,211.
In 2028, HAE is forecast to generate $70,950,979,351 in revenue, with the lowest revenue forecast at $68,752,470,155 and the highest revenue forecast at $72,509,443,612.